Prognostic Impact of Initial Prostate Specific Antigen Half‐Life After Abiraterone Acetate in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: Who May Need Triplet Therapy?

Documenti analoghi

• Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis
  di: Kotaro Suzuki, et al.
  Pubblicazione: (2025)
• Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Multi‐Institutional Analysis
  di: Kotaro Suzuki, et al.
  Pubblicazione: (2025)
• The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
  di: Yifu Shi, et al.
  Pubblicazione: (2025)
• Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
  di: Mitsuhisa Nishimoto, et al.
  Pubblicazione: (2025)
• Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide
  di: Christian Andrés Martínez Osorio, et al.
  Pubblicazione: (2025)